Volume : 10, Issue : 07, July – 2023
Title:
04.GUIDANCE FOR INDUSTRY QUALITY SYSTEMS APPROACH TO PHARMACEUTICAL CGMP REGULATIONS
Authors :
Pasuladhi Ramya, Dr.S .A. Sreenivas
Abstract :
This guidance is intended to help manufacturers implementing modern quality systems and risk management approaches to meet the requirements of the Agency’s current good manufacturing practice (CGMP) regulations (2l CFR parts 210 and 211). The guidance describes a comprehensive quality systems (QS) model, highlighting the model’s consistency with the CGMP regulatory requirements for manufacturing human and veterinary drugs, including biological drug products. Implementation of a comprehensive quality systems model for human and veterinary pharmaceutical products, including biological products, will facilitate compliance with 21 CFR parts 210 and 211. The central goal of a quality system is the consistent production of safe and effective products and ensuring that these activities are sustainable. Quality professionals are aware that good intentions alone will not ensure good products. A robust quality system will promote process consistency by integrating effective knowledge-building mechanisms into daily operational decisions. Both good manufacturing practice and good business practice require a robust quality system. When fully developed and effectively managed, a quality system will lead to consistent, predictable processes that ensure that pharmaceuticals are safe, effective, and available for the consumer.
Key words: Guidance, Industry, Quality Systems, Pharmaceutical CGMP Regulations
Cite This Article:
Please cite this article in press : Pasuladhi Ramya et al, Guidance For Industry Quality Systems Approach To Pharmaceutical CGMP Regulations., Indo Am. J. P. Sci, 2023; 10 (07).
Number of Downloads : 10
References:
1. 1978 Preamble to the Good Manufacturing Practice Final Regulations – Federal Register
Docket No. 73N-0339] http://www.fda.gov/cder/dmpq/preamble.txt
2. CPGM 7356.002 Compliance Program – Drug Manufacturing Inspections http://www.fda.gov/cder/dmpq/compliance_guide.htm
3. Quality Planning and Analysis, 3rd Ed. by J.M. Juran, F.M. Gryna (McGraw-Hill, New York, N.Y. 1993)
4. ANSI/ISO/ASQ Q9000-2000: Quality management systems – Fundamentals and vocabulary,
(American Society for Quality, 2000)
5. Guideline of General Principles of Process Validation, May 1987 – http://www.fda.gov/cder/guidance/pv.htm
6. FDA Compliance Policy Guide 7132c.08 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval, updated 03-12-2004 – http://www.fda.gov/ora/compliance_ref/cpg/cpgdrg/cpg490-100.html
7. Guidance for Industry – Sterile Drug Products Produced by Aseptic Processing Current Good Manufacturing Practice – September 2004. See also the draft guidance on investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.
8. FDA Compliance Policy Guide Sec. 130.300, FDA Access to Results of Quality Assurance Program Audits and Inspections, (CPG 7151.02) http://www.fda.gov/ora/compliance_ref/cpg/cpggenl/cpg130-300.html
9. Criteria for Performance Excellence, Business (Baldrige National Quality Program, NIST 2003) http://baldrige.nist.gov/PDF_files/2003_Business_Criteria.pdf
10. ANSI/ISO/ASQ Q9001-2000: Quality management systems – Requirements (American Society for Quality, 2000)
11. ANSI/ISO/ASQ Q9004-2000: Quality management systems – Guidelines for performance improvement (American Society for Quality, 2000)
12. ANSI/ISO 17025-1999: General requirements for the competence of testing and calibration laboratories (American Society for Quality, 1999)
13. CMMI-SE/SW, V1.1: Capability Maturity Model Integration for Systems Engineering and Software Engineering, Staged Representation (Software Engineering Institute, Carnegie Mellon University, 2002) http://www.sei.cmu.edu/pub/documents/02.reports/pdf/02tr002.pdf
14. The Balanced Scorecard Institute: http://balancedscorecard.org
15. Guidance for Developing Quality Systems for Environmental Program (EPA QA/G-1, Nov 2002) http://www.epa.gov/quality/qs-docs/g1-final.pdf
16. Guidance for Industry Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients (U.S. Department of Health and Human Services/ Food and Drug Administration, August 2001) . Good Manufacturing Practices for Pharmaceutical Products: Main Principles (World Health Organization Technical Report Series, No. 908, 2003) http://www.who.int/medicines/library/qsm/trs908/trs908-4.pdf
17. Procedures For The Implementation of The Federal Managers’ Financial Integrity Act (FMFIA); (FDA Staff Manual Guide 2350.1)
18. Managing the Risks from Medical Product Use: Creating a Risk Management Framework
(U.S. FDA, 1999) http://www.fda.gov/oc/tfrm/1999report.html
19. Framework for Environmental Health Risk Assessment – Final Report, Vol.1 (Presidential/Congressional Commission on Risk Assessment and Risk Management, 1997) http://www.riskworld.com/Nreports/1997/risk-rpt/pdf/EPAJAN.PDF
20. Report on FDA Quality System Framework for Pharmaceutical Product Regulation Activities; (Quality System Framework Subcommittee, December 2003)
21. Tutorials for Continuous Quality Improvement (Clemson University, 1995) http://deming.eng.clemson.edu/pub/tutorials/
22. Variation Risk Management – Focusing Quality Improvement in Product Development and Products by Anna C. Thornton (John Wiley and Sons, Inc.; Hoboken, New Jersey, 2004
23. Guidance for Industry for the Submission of Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products – http://www.fda.gov/cder/guidance/cmc2.pdf
24. Chapter 3, “Quality Management in the American Pharmaceutical Industry,” in
Pharmaceutical Quality, Ed. by R. Prince (DHI Publishing, River Grove, IL, 2004)
</div8